2020-China's new drug License-out outbreak.

All along,“innovative medicine”There are difficulties in research and development, high investment, long cycle and other problems, but in the long run, the research and development capacity of innovative drugsStillIt is the core competitiveness of pharmaceutical companies. In the process of promoting China's innovative drugs to the world, a large number of pharmaceutical companies focusing on innovative research and development are also developing rapidly..Enter2020years since,Chinese New DrugAuthorized transactions (License in/out) The number of innovative drugs in China has increased sharply compared to previous years.License-outCooperation authorizationSignificant increase in number, can be describedLicense-outA year of great eruptions.

10Month29day,Fosun PharmaceuticalAnnounced, its holding subsidiary, Fuchuang Pharmaceuticals, has been in cooperation with Eli Lilly (Eli Lilly and Company) sign the License Agreement,Awarded Lilly on Recovery MedicineBCL-2inhibitorsFCN-338Exclusive interests in other regions of the world except Mainland China, Hong Kong and Macau.Cooperation involvesAmount up4.4Billions of dollars.

10Month27On the same day, Cornerstone Pharmaceuticals announced.,withEQRxThe company reached a strategic cooperation. Cornerstone Pharmaceuticals will be exclusively licensedEQRxThe company develops and commercializes resistance outside of Greater China.PD-L1Mab suglicumab (CS1001) and resistancePD-1Monoclonal antibodyCS1003.Cooperation involves amounts up13Billions of dollars.

9Month28Japan, Hengrui MedicineAnnounce,already with South KoreaHLB Life ScienceCompany (referred to“HLB-LSCompany”) to reach an agreement1.057The total amount of the transaction of US $100 million will be its own intellectual property rights of the anti-tumor drug pyrrotinib maleate tablets (referred to“Piritinib”) Project paid license to South KoreaHLB-LScompany, and obtainedHLB-LSThe company's sales share.

9Month4On the same day, Sky Bio and AbbVie jointly announced that they had developed an innovative technology independently developed by Sky Bio for the treatment of a variety of cancers.CD47monoclonal antibodyLemzoparlimab(TJC4) the development and commercialization of the establishment of global strategic cooperation, the total amount of cooperation or near.30billion dollars, setting a new record for the transfer of product rights and interests of China's innovative pharmaceutical companies.

8Moon, Cinda CreatureAnnounce,Lilly will be awardedDabershu®(Sindilizumab Injection)With an exclusive license outside of China, Lilly will work to bring Sindiliximab to North America, Europe and beyond.

6Month9Day,Corning Jerry announced,withSanofi has signed an agreement to reach a strategic cooperation: will jointly targetHER2Positive cancer cancer patients, advanceKN026With Taxote®(Docetaxel)Clinical trials of drug combinations. Under the terms of the agreement, upon reaching certain clinical milestones, Sanofi will have the right to negotiate aKN026the right to introduce an exclusive license.

6Month1Day,GarcothAnnounce,An authorized transaction with AbbVie.according to the agreement,The two companies will jointly develop and commercialize protein tyrosine phosphatases that act on key targets in cancer cells and immune cells.(SHP2)inhibitors,AbbVie will get GacosSHP2Exclusive license of the project.

5Month4Day,Junshi biological announced,With Eli Lilly (Eli Lilly and Company) Signed the R & D Cooperation and Licensing Agreement, which will cooperate in R & D and commercialization.SARS-CoV-2Neutralizing antibody (abbreviated as: Junshi Xinguan antibody, product code:JS016). Under the agreement, Eli Lilly will be granted a right to invest outside of Greater China.JS016Exclusive license to carry out research and development activities, production and sales.Amount involved in cooperation2.55Billions of dollars.

4Month20day,Hengrui MedicineAnnounce,with South KoreaCrystalGenomics Inc.The Company signs an agreement8775The total amount of transactions will bePD-1Monoclonal Antibody Karilli Bead Project LicensedCGcompanies, while acquiringCGThe company's share of sales,CGThe Company will acquire the exclusive clinical development, registration and marketing rights for carellizumab in South Korea and will be licensed to develop and market carellizumab for all human diseases.

4Month15day,LEO PharmaAnnounced,With the integration of biotechnology (Oneness Biotech) and Zhongtian (Shanghai) Biology (Shanghai Microbium) Signed an exclusive global license agreement to acquire an antibody drug candidate under the company.FB825development and commercialization interests. According to the agreement,LEO Pharmawill pay4000$10,000 in advance and provide up5.3Milestone payments of $100 million, and subsequent potential royalties.

4Month8Day,Chengdu PilotAnnounced,With Tanbian Mitsubishi Pharmaceutical Co., Ltd. (referred to“MTPC”) to enter into a new drug R & D transfer agreement. The transfer agreement includes a series of new structures of small molecule lead compounds, specifically targetedMTPCDesignated undisclosed targets. In accordance with the agreement,MTPCwill beChengdu Pilotpayment of the transfer fee, whileChengdu PilotExclusively transfer the subsequent development and commercialization interests of these small molecule compoundsMTPC.

3Month31Day,Fu Hong Han LinXuanCloth, andMabxience Research, S.L.enter into an exclusive license agreement. GrantMabxienceDevelopment and commercialization of oncology treatments in Argentina, Uruguay and ParaguayHLX02Exclusive license of the product.Amount involved in cooperation75million dollars.

3Month11Day,Chengdu pilot nounces,with Japanese scientific researchPharmaceuticalCorporation (Jaken Pharmaceutical Co. Ltd., shortJaws) to enter into a new drug R & D transfer agreement. In accordance with the agreement,JawsA transfer fee will be paid to Chengdu Pilot, which will exclusively transfer the subsequent development and commercialization interests of these small molecule compounds to Chengdu Pilot.Jaws.

1Month14Day, Cinda Creatures announced,Bevacizumab biosimilar(IBI305)Commercialization interests in the United States and Canada are authorizedCoherus BioSciences.Cooperation involves goldUh4500million dollars.

Local pharmaceutical companieslicense outNumber of transactionsincreasing year by year, reflectIt'sThe R & D strength of China's local pharmaceutical companies is gradually increasing.